Updates are available Correction dated 2023-03-26

Article History

Received: 21 September 2022

Accepted: 27 January 2023

First Online: 4 February 2023

Change Date: 26 March 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00280-023-04522-x

Declarations

:

: R. Kim reports honoraria fees from Pfizer and QED; and consulting fees from Incyte, Bayer, and Taiho. A. D. Leal reports employment with ClinicalPath Oncology, as a Pancreatic/Neuroendocrine Committee Chair; and research funds from Bristol Myers Squibb (Institution, Exelixis (Institution), Arrys Therapeutics, Inc. (Institution), Hutchinson Medipharma LTD (Institution), Corcept Therapeutics (Institution), AbbVie (Institution), and Conjupro Biotherapeutics, Inc (Institution). A. Parikh reports ownership of stock/shares from Equity for C2i genomics for SAB; consulting fees from Pfizer, Eli Lilly, Roche, and Inivita and other potential financial relationships with research to the institution Puretech in the last 12 months, PMV Pharma, Plexxicon, Takeda, Bristol Myers Squibb, Novartis, Mirati, Genentech, and Daiichi Sankyo. D. P. Ryan reports ownership of stock/shares from MPM Capital and Exact Sciences, honoraria fees from MPM Capital, consulting fees from Boehringer Ingelheim, grants or funds from SU2C, and other potential financial relationships with UpToDate and McGraw Hill. S. Wang reports potential employment conflict and ownership of stock/shares with Takeda Inc. B. Bahamon reports potential employment conflict with Takeda Development Center Americas, Inc. N. Gupta and H. Miao report potential employment conflict and ownership of stock/shares with Takeda. A. Moss reports consulting fees with Takeda. J. Pye reports potential employment conflict with Takeda. H. Inguilizian reports potential employment conflict with Takeda Pharmaceutical. J. M. Cleary reports honoraria fees from Syros Pharmaceuticals and Blueprint Medicines; grants/funds from AbbVie (Institution), Merus (Institution), Roche (Institution), Bristol Myers Squibb (Institution), Merck, AstraZeneca, Esperas Pharma, Bayer, and Tesaro.

: The study was conducted with the highest respect for the participants according to the protocol, the ethical principles that have their origin in the Declaration of Helsinki, and the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice. The protocol was approved by the relevant central or local Independent Review Boards or Independent Ethics Committees.

: All patients provided written informed consent.

: Since all data are anonymized before publication, no additional consents were obtained.